

Jie-Fu Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11317148/publications.pdf>

Version: 2024-02-01

38
papers

999
citations

759233

12
h-index

610901

24
g-index

40
all docs

40
docs citations

40
times ranked

1783
citing authors

#	ARTICLE	IF	CITATIONS
1	Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.. Journal of Clinical Oncology, 2021, 39, 167-167.	1.6	1
2	A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.. Journal of Clinical Oncology, 2021, 39, e17008-e17008.	1.6	0
3	Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. American Journal of Clinical and Experimental Urology, 2021, 9, 350-366.	0.4	0
4	Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications. Advanced Materials, 2020, 32, e1903663.	21.0	66
5	Circulating Rare Cells: Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications (Adv. Mater. 1/2020). Advanced Materials, 2020, 32, 2070008.	21.0	0
6	Clinical Decision Support for Ovarian Carcinoma Subtype Classification: A Pilot Observer Study With Pathology Trainees. Archives of Pathology and Laboratory Medicine, 2020, 144, 869-877.	2.5	7
7	Development of a circulating tumor cell-based RNA classifier for patients with castration-resistant prostate cancer: CTC-PCS/PAM50.. Journal of Clinical Oncology, 2020, 38, e17509-e17509.	1.6	1
8	Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, e17512-e17512.	1.6	0
9	Prostate cancer CTC-RNA Assay: A new method for contemporary genomics and precision medicine via liquid biopsy.. Journal of Clinical Oncology, 2020, 38, 170-170.	1.6	1
10	Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 168-168.	1.6	0
11	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Theranostics, 2019, 9, 2812-2826.	10.0	20
12	A noninvasive prognostic biomarker for metastatic castration-resistant prostate cancer: Very small nuclear circulating tumor cells.. Journal of Clinical Oncology, 2019, 37, 179-179.	1.6	0
13	A circulating tumor cell RNA assay for dynamic assessment of androgen receptor signaling inhibitors sensitivity in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 157-157.	1.6	0
14	A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5059-5059.	1.6	0
15	Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. Journal of Medicinal Chemistry, 2018, 61, 2052-2061.	6.4	49
16	RNA Biomarkers: Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection (Adv. Healthcare Mater. 3/2018). Advanced Healthcare Materials, 2018, 7, 1870013.	7.6	3
17	NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Advanced Drug Delivery Reviews, 2018, 125, 78-93.	13.7	89
18	Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. Advanced Healthcare Materials, 2018, 7, 1700701.	7.6	38

#	ARTICLE	IF	CITATIONS
19	Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. <i>Cancer Research</i> , 2018, 78, 6086-6097.	0.9	49
20	Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. <i>Cancer Medicine</i> , 2018, 7, 4639-4649.	2.8	12
21	NanoVelcro CTC purification systems for expressional analysis of circulating tumor cells from prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 295-295.	1.6	0
22	Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17063-e17063.	1.6	0
23	Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2018, 6, 43-54.	0.4	5
24	Imprinted NanoVelcro Microchips for Isolation and Characterization of Circulating Fetal Trophoblasts: Toward Noninvasive Prenatal Diagnostics. <i>ACS Nano</i> , 2017, 11, 8167-8177.	14.6	68
25	Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5031-5031.	1.6	0
26	Circulating tumor cells in prostate cancer: beyond enumeration. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 63-73.	0.3	6
27	Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. <i>Theranostics</i> , 2016, 6, 1425-1439.	10.0	56
28	Applications of circulating tumor cells for prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 254-259.	1.2	4
29	A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 208-208.	1.6	1
30	Very small nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 64-64.	1.6	0
31	A phase 2 study of cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16552-e16552.	1.6	0
32	Very-small-nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis (VM) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16530-e16530.	1.6	0
33	A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. <i>Oncotarget</i> , 2015, 6, 44781-44793.	1.8	94
34	Supramolecular Nanosubstrate-Mediated Delivery for Reprogramming and Transdifferentiation of Mammalian Cells. <i>Small</i> , 2015, 11, 2499-2504.	10.0	12
35	Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. <i>Cancer</i> , 2015, 121, 3240-3251.	4.1	89
36	Programming Thermoresponsiveness of NanoVelcro Substrates Enables Effective Purification of Circulating Tumor Cells in Lung Cancer Patients. <i>ACS Nano</i> , 2015, 9, 62-70.	14.6	118

#	ARTICLE	IF	CITATIONS
37	Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases.. Journal of Clinical Oncology, 2015, 33, 11027-11027.	1.6	0
38	Nanostructure Embedded Microchips for Detection, Isolation, and Characterization of Circulating Tumor Cells. Accounts of Chemical Research, 2014, 47, 2941-2950.	15.6	202